[go: up one dir, main page]

AU2003299399A1 - Use of a specific inhibitor of the 5ht2b receptor for the treatment of cancer - Google Patents

Use of a specific inhibitor of the 5ht2b receptor for the treatment of cancer

Info

Publication number
AU2003299399A1
AU2003299399A1 AU2003299399A AU2003299399A AU2003299399A1 AU 2003299399 A1 AU2003299399 A1 AU 2003299399A1 AU 2003299399 A AU2003299399 A AU 2003299399A AU 2003299399 A AU2003299399 A AU 2003299399A AU 2003299399 A1 AU2003299399 A1 AU 2003299399A1
Authority
AU
Australia
Prior art keywords
cancer
treatment
specific inhibitor
5ht2b receptor
5ht2b
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003299399A
Other versions
AU2003299399A8 (en
Inventor
Hugues Bienayme
Laurent Chene
Serge Grisoni
Alain Latil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Urogene SA
Original Assignee
Urogene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urogene SA filed Critical Urogene SA
Publication of AU2003299399A1 publication Critical patent/AU2003299399A1/en
Publication of AU2003299399A8 publication Critical patent/AU2003299399A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003299399A 2002-12-26 2003-12-23 Use of a specific inhibitor of the 5ht2b receptor for the treatment of cancer Abandoned AU2003299399A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR02/16699 2002-12-26
FR0216699A FR2849382A1 (en) 2002-12-26 2002-12-26 USE OF THE HTR2B GENE FOR THE TREATMENT OF PROSTATE CANCER
PCT/FR2003/003875 WO2004060390A2 (en) 2002-12-26 2003-12-23 Use of a specific inhibitor of the 5ht2b receptor for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2003299399A1 true AU2003299399A1 (en) 2004-07-29
AU2003299399A8 AU2003299399A8 (en) 2004-07-29

Family

ID=32480198

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003299399A Abandoned AU2003299399A1 (en) 2002-12-26 2003-12-23 Use of a specific inhibitor of the 5ht2b receptor for the treatment of cancer
AU2003303568A Abandoned AU2003303568A1 (en) 2002-12-26 2003-12-23 Use of a non-specific inhibitor of the 5ht2b receptor for the treatment of prostate cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003303568A Abandoned AU2003303568A1 (en) 2002-12-26 2003-12-23 Use of a non-specific inhibitor of the 5ht2b receptor for the treatment of prostate cancer

Country Status (3)

Country Link
AU (2) AU2003299399A1 (en)
FR (1) FR2849382A1 (en)
WO (2) WO2004060390A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ592289A (en) * 2007-04-13 2013-03-28 Southern Res Inst Anti-Angiogenic Agents and Methods of Use
US11034751B1 (en) 2018-01-30 2021-06-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating cancer using serotonin receptor inhibitors
WO2023053142A1 (en) * 2021-09-30 2023-04-06 National Centre For Cell Science Novel combination of serotonin receptor (5-htr2b) antagonist and an immunomodulator and chemotherapeutic drugs for inhibition of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2265695A (en) * 1995-01-17 1996-08-07 Pfizer Inc. The use of sertraline to treat cancer patients
US5958934A (en) * 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
FR2810677B1 (en) * 2000-06-27 2004-10-01 Urogene PROCESS FOR IN VITRO DIAGNOSIS OF PROSTATE CANCER AND IMPLEMENTATION KIT
US6444477B1 (en) * 2000-11-28 2002-09-03 Pharmagene Laboratories Limited Assay method for detecting 5-HT2B antagonists
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs

Also Published As

Publication number Publication date
WO2004061408A2 (en) 2004-07-22
FR2849382A1 (en) 2004-07-02
AU2003299399A8 (en) 2004-07-29
WO2004061408A3 (en) 2004-08-19
WO2004060390A3 (en) 2004-08-19
AU2003303568A1 (en) 2004-07-29
AU2003303568A8 (en) 2004-07-29
WO2004060390A2 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
AUPS054702A0 (en) Cancer therapy
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
AU2003224654A1 (en) Photodynamic therapy for pre-melanomas
AU2003266949A1 (en) Compounds
AU2003221098A1 (en) Oligofluorenylene compounds
AU2003224076A1 (en) Antibody combination useful for tumor therapy
AU2003272069A1 (en) Novel floating dosage form
AU2003212634A1 (en) Compounds useful in the treatment of cancer
AU2003256655A1 (en) Therapeutic compounds for treating dyslipidemic conditions
AU2003247005A1 (en) Therapy combination
AU2003222449A1 (en) Medicine for treating cancer
AU2003245794A1 (en) Glycosaminoglycan-dnase combination therapy
AU2003215150A1 (en) Therapeutic compounds
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003244080A1 (en) Phosphodiesterase inhibitor
AU2003256323A1 (en) Sos1 inhibitors
AU2003257840A1 (en) Transformer
AU2003296545A1 (en) Use of a trpm8-activating substance for the treatment of tumours
AU2003299399A1 (en) Use of a specific inhibitor of the 5ht2b receptor for the treatment of cancer
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
AU2003283339A1 (en) Cancer therapy determination
AU2003260509A1 (en) Acetylene compounds
AU2003201729A1 (en) Transformer
AU2003232606A1 (en) Surface reactor
GB0208392D0 (en) Therapeutic compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase